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SerotoninThe most effective treatment for Parkinson's disease (PD), L-DOPA, induces dyskinesia after prolonged use. We
have previously shown that in 6-hydroxydopamine (6-OHDA) lesioned rats rendered dyskinetic by prolonged
L-DOPA administration, lesion of the subthalamic nucleus (STN) reduces not only dyskinesias but also buspirone
antidyskinetic effect. This study examined the effect of buspirone on STNneuron activity. Cell-attached recordings
in parasagittal slices from naïve rats showed thatwhilst serotonin excited themajority of STN neurons, buspirone
showed an inhibitorymain effect but only in 27% of the studied cellswhichwas prevented by the 5-HT1A receptor
selective antagonistWAY-100635. Conversely, single-unit extracellular recordingswere performed in vivo on STN
neurons from four different groups, i.e., control, chronically treated with L-DOPA, 6-OHDA lesioned and lesioned
treatedwith L-DOPA (dyskinetic) rats. In control animals, systemic-buspirone administration decreased the ﬁring
rate in a dose-dependent manner in every cell studied. This effect, prevented by WAY-100635, was absent in
6-OHDA lesioned rats and was not modiﬁed by prolonged L-DOPA administration. Altogether, buspirone in vivo
reduces consistently the ﬁring rate of the STN neurons through 5-HT1A receptors whereas ex vivo buspirone
seems to affect only a small population of STN neurons. Furthermore, the lack of effect of buspirone in 6-OHDA
lesioned rats, suggests the requirement of not only the activation of 5-HT1A receptors but also an intact
nigrostriatal pathway for buspirone to inhibit the STN activity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As a consequence of long-term treatment with L-DOPA, the most
effective drug to alleviate motor symptoms in Parkinson's disease (PD),
patients develop L-DOPA-induced dyskinesia (LID). This motor disorder
can be completely disabling for the patient, sometimes reducing quality
of life evenmore than PD itself. In spite of a large number of clinical trials
for ﬁnding an efﬁcient therapy to reduce LID, the only currently available
antidyskinetic drug so far, is the anti-inﬂuenza agent amantadine (Fox,oxydopamine; aCSF, artiﬁcial
OPA-induced dyskinesia; PD,
e hydroxylase.
. This is an open access article under2013). Unfortunately, prescription of amantadine raises some controver-
sy about its long-term antidyskinetic efﬁcacy (Thomas et al., 2004; Wolf
et al., 2010).
Serotonin (5-HT)-based therapies have been extensively investigated
in an attempt to ﬁnd efﬁcacious antidyskinetic drugs. Indeed, numerous
5-HT agonists have been shown to improve dyskinesia, although not
always without worsening the antiparkinsonian effect (Bibbiani et al.,
2001; Dupre et al., 2007; Kleedorfer et al., 1991). For example, sarizotan,
a 5-HT1A receptor agonist, improves dyskinesia in macaque (Gregoire
et al., 2009) and rat models (Gerlach et al., 2011a). However, it failed in
a III-phase clinical trial on PD patients (Goetz et al., 2007) due to the
fact that sarizotan did not counteract LIDs better than placebo. Also, a
single dose of eltoprazine, a 5-HT1A/B-receptor agonist, has recently
shown antidyskinetic effects in a placebo-controlled phase I/IIa study
(Svenningsson et al., 2015) though no data are yet available about its
long treatment efﬁcacy.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Peroutka, 1988) has antidyskinetic properties not only in 6-
hydroxydopamine (6-OHDA) lesioned rats (Aristieta et al., 2012;
Azkona et al., 2014; Dekundy et al., 2007; Eskow et al., 2007; Gerlach
et al., 2011b) but also in open-label trials performed in humans
(Bonifati et al., 1994; Kleedorfer et al., 1991; Politis et al., 2014). Inter-
estingly, buspirone, apart from being a partial agonist for 5-HT1A
heteroreceptors, behaves as a full agonist for 5-HT1A-autoreceptors
(Sussman, 1998) in the dorsal raphe nucleus (DRN) inhibiting the
serotonergic neuron ﬁring activity (VanderMaelen et al., 1986). Also, it
is important to mention that, although buspirone has afﬁnity mainly
for 5-HT1A receptors, it also acts as an antagonist for D2 and D3
dopamine receptors (Bergman et al., 2013; Dhavalshankh et al., 2007;
McMillen et al., 1983). In fact, buspirone reduces graft-induced dyskine-
sia in a rat model of PD by a mechanism which is independent from
activation of either pre- or post-synaptic 5-HT1A receptor (Shin et al.,
2012). All these peculiarities could help to explain why buspirone is
an efﬁcacious antidyskinetic drug and make it interesting to ﬁgure out
the target through what buspirone elicits its antidyskinetic effect.
The subthalamic nucleus (STN) is the only glutamatergic nucleus of
the basal ganglia and exerts the principal excitatory effect on the output
nuclei of the basal ganglia, playing a critical role in the motor circuit.
Local infusion of a stimulatory 5-HT2C-receptor agonist into the STN
induces orofacial dyskinesia in rat (Eberle-Wang et al., 1996).Moreover,
we reported that when the STN is lesioned the antidyskinetic effect of
buspirone is decreased (Aristieta et al., 2012). Therefore, the aim of
this study was to investigate the effect induced by buspirone on the
STN neuronal activity not only in brain slices but also in anaesthetized
control and 6-OHDA lesioned rats chronically treated with saline or
L-DOPA.
2. Materials and methods
2.1. Animals
Female Sprague–Dawley rats weighing 200–280 g for in vivo exper-
iments and male Sprague–Dawley rats weighing 50–75 g for ex vivo
experiments were housed in groups of six with free access to food and
water in environmentally controlled conditions (20 ± 2 °C; 65–70% of
relative humidity and a 12 h:12 h light/dark cycle). Every effort was
made to minimize animal suffering, to use the minimum number of
animals per group and experiment and to utilize alternatives to in vivo
techniques if available. Experimental procedures were approved by
the Local Ethical Committee of the University of Basque Country (UPV/
EHU, CEBA/185/2011), following European (2010/63/UE) and Spanish
(RD 1201/2005) regulations for the care and use of laboratory animals.
2.2. 6-OHDA lesion and L-DOPA treatment
6-OHDA lesionswere performed according to our established proto-
cols (Aristieta et al., 2012; Miguelez et al., 2011). Rats were pretreated
30 min before anesthesia with desipramine (25 mg/kg, i.p.) in order to
preserve the noradrenergic terminals. Then, rats were anesthetized
with isoﬂurane inhalation and placed in the stereotaxic frame (David
Kopf® Instruments). Lesions were performed by two injections of
6-OHDA of 7.5 μg and 6 μg, respectively (3.5 μg/μl saline with
0.02% ascorbic acid) in the right medial forebrain bundle: 2.5 μl at
anteroposterior (AP)−4.4 mm, mediolateral (ML) +1.2 mm and dor-
soventral (DV)−7.8mm, relative to bregmaanddurawith the toothbar
set at−2.4, and 2 μl at AP−4.0 mm, ML +0.8 mm, and DV−8 mm,
with toothbar at +3.4 (Paxinos and Watson, 1986). Sham animals
were similarly treated but instead of 6-OHDA received vehicle. For the
administration of the neurotoxin a 10 μl-Hamilton syringe was used
and the infusion rate was 1 μl/min. Prior to the administration, the
toxin was kept protected from light and in ice. Two weeks later, theseverity of the 6-OHDA lesion was evaluated by rotational behavior
over 90 min after d-amphetamine (3 mg/kg, i.p.) administration, and
only severely lesioned animals were selected for this study (more
than 5 full-body ipsilateral turns/min).
Rats were divided in four different groups depending on the lesion
and pharmacological treatment followed: control, sham L-DOPA,
6-OHDA lesioned and 6-OHDA lesioned plus L-DOPA (dyskinetic) rats.
Animalswere treated chronically over 3weekswith saline in the control
and 6-OHDA lesion groups; or with L-DOPA (6 mg/kg + benserazide-
HCl (12 mg/kg s.c.) in sham L-DOPA and the dyskinetic groups. On
day 21, the dyskinetic movements were scored as described by
Miguelez et al. (2011). All 6-OHDA lesioned animals chronically treated
with L-DOPA developed severe dyskinetic movements that reached the
peak between 40 and 80min after a single injection of L-DOPA (Fig. 1A).
Tyrosine hydroxylase (TH)-immunostaining was used to examine the
degree of dopaminergic denervation in the striatum and the substantia
nigra following the methodology described by Miguelez et al. (2011)
and in all cases the loss of striatal DA ﬁbers was N90% (Fig. 1B).
2.3. Electrophysiological recordings
2.3.1. Ex vivo recordings
Male Sprague Dawley rats (50–75 g) were anesthetized with chloral
hydrate (400 mg/kg, i.p.) and sacriﬁced by decapitation. The brain was
rapidly dissected out and placed in ice-cold cutting solution containing
(in mM): 20 NaCl, 2.5 KCl, 0.5 CaCl2, 7 MgCl2, 1.25 NaH2PO4, 85 sucrose,
25 D-glucose and 60 NaHCO3, saturated with 95% O2/5% CO2. The
cerebellum was removed and brain hemispheres were separated along
the inter-hemispheres line. Parasagittal brain slices (300–350 μm thick)
containing the STN, identiﬁed as a lens-shaped dense patch located
medial to the internal capsule, were cut and immediately placed in the
artiﬁcial cerebrospinal ﬂuid (aCSF) composed of (mM) 126 NaCl, 2.5
KCl, 1.2 MgCl2, 2.4 CaCl2, 1.2 NaH2PO4, 11.1 D-glucose, 21.4 NaHCO3,
0.1 ascorbic acid, and saturated with 95% O2/5% CO2 at 33 °C. After
at least one hour resting at 33 °C, the slice was submerged in a slice
chamber (0.5 ml) mounted on the microscope stage and superfused
(2.5–3 ml/min) with the aCSF bathing solution at 31 °C.
STN neurons were visually identiﬁed using an upright microscope
with infrared optics (Eclipse E600FN, Nikon®) equipped with a 40×
water-immersion objective. Patch electrodes were pulled from borosil-
icate glass capillaries (World Precision Instruments) on a two-stage
puller (PC-10, Narishige) to a pipette resistance of 3–5 MΩ. Recordings
were made with an Axopatch 200B ampliﬁer and digitized with a
Digidata 1322A (Axon Instruments®). To accurately examine spontane-
ous ﬁring in STN neurons, pipettes were ﬁlled with aCSF and recordings
were performed in the minimally invasive cell-attached loose patch
conﬁguration (20–30 mΩ seal resistance). Data were low-pass ﬁltered
at 5 kHz before being digitized at a rate of 10 kHz. Acquisition and all
subsequent analysis were carried out with Clampex 10.4. Firing rate
histograms were generated by integrating action potential discharge
in 10 s bins (Fig. 1C). 54 cells ﬁred spontaneously and regularly at
13 ± 1 Hz. Only 5 neurons ﬁred in burst mode and 4 cells remained
silent. This proportion of regularly ﬁring neurons strongly resembles
what has been described in the literature (98%) for ex vivo STN cells
(Wilson et al., 2004). Also, an increase in the temperature from 31 to
35 °C induced a reversible increase in the average frequency of sponta-
neous ﬁring rate from 13 ± 4 Hz to 19 ± 7 Hz (n = 6; paired t test,
p b 0.05) (Fig. 1D) as it has been described for this nucleus (Heida
et al., 2008). All drugs were applied in the perfusion solution in
known concentrations.
2.3.2. In vivo recordings
All STN neuron electrophysiological recordings in vivo were
performed as described by Morera-Herreras et al. (2011), twenty-four
hours after the last saline or L-DOPA injection. Rats were anesthetized
with urethane (1.2 g/kg, i.p.) and placed in a stereotaxic frame with its
Fig. 1. Examples of behavioral, histological and electrophysiological procedures. (A) Dyskinesia scores evaluated after a single injection of L-DOPA on the last testing session (day 21).
(B) Representative tyrosine hydroxylase (TH) immunostaining in the striatum and the substantia nigra showing the loss of TH positive ﬁbers in rats microinfused unilaterally with
6-OHDA into the right nigrostriatal pathway. (C) Typical spontaneous spikes (action potentials, ~13 Hz) in a presumed STN neurons recorded ex vivo in cell-attached mode. (D) Pooled
data of the average frequency of spontaneous ﬁring rate recorded ex vivo at 31 °C and later at 35 °C showing a signiﬁcant increase (n = 6; paired t test, *p b 0.05). (E) Distribution of
the in vivo recording sites in the STN. The STN is marked in gray, framed and expanded; and perpendicular lines show laterality and depth. Image modiﬁed from Paxinos and Watson
(1986), with permission from Elsevier. (F) Samples of spontaneous spiking activity recorded in vivo in the STN of tonic ﬁring pattern, in which the density histogram follows a Gaussian
distribution (top) and a bursting ﬁring pattern, in which the density histogram represents a distribution signiﬁcantly different from Poisson distribution (bottom).
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lowered into the right STN (relative to bregma and dura: AP−3.7 mm,
ML−2.5 mm and DV−7/−8.5 mm). The extracellular signal from the
electrode was ampliﬁed with a high-input impedance ampliﬁer and
wasmonitored on an oscilloscope and on an audiomonitor. All recorded
STN neurons exhibited a biphasic waveform and a spike width of 1.0 to
1.5 ms (Hollerman and Grace, 1992). Neuronal spikes were digitized
using computer software (CED micro 1401 interface and Spike2 soft-
ware, Cambridge Electronic Design). The basal ﬁring rate was recorded
for 5 min.
Local injection of buspirone close to the STN neuron which was
being recorded was performed as described by Ruiz-Ortega and Ugedo
(1997). Pressure pulses (50–150 ms) were applied to a calibrated
pipette, glued adjacent to a recordingmicropipette, containing buspirone(0.25 M) dissolved in Dulbecco's buffered saline solution (NaCl,
136.9 mM; KCl, 2.7 mM; NaH2PO4, 8.1 mM; KH2PO4, 1.5 mM; MgCl2,
0.5 mM and CaCl2, 0.9 mM, pH 7.4). The volume of each ejection pulse
was measured by monitoring the meniscus movement in the calibrate
pipette.
At the end of each electrophysiological experiment, a Pontamine Sky
Blue mark was deposited for posterior veriﬁcation of the recording site
using neutral red staining. Only cells recorded within the STN were
included in this study (Fig. 1E). The ﬁring parameters of STN neurons
were analyzed off-line using Spike2 software. The following parameters
were calculated: ﬁring rate, coefﬁcient of variation and ﬁring pattern.
The different ﬁring patterns could be analyzed according to themethod
described by Kaneoke and Vitek (1996) (Fig. 1F). The analyzed spike-
trains lasted more than 120 s and contained at least 300 spikes.
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Drugs used in this study were: 6-OHDA (3.5 μg/μl) dissolved in
MiliQ water containing 0.02% ascorbic acid; desipramine hydrochloride
(25 mg/kg i.p.), amphetamine sulfate (3 mg/kg i.p.), chloral hydrate,
L-DOPA (6 mg/kg s.c.), benserazide-HCL (12 mg/kg s.c.), serotonin
hydrochloride (5-HT, 30 μM ex vivo), buspirone hydrochloride (4 and
8 mg/kg, i.p. in vivo; 10 and 30 μM ex vivo) and WAY-100635 maleate
salt (0.5 and 1.5 mg/kg, i.p. in vivo; 1 μM ex vivo) from Sigma-Aldrich
disolved in 0.9% saline or Dulbecco for in vivo experiments and dissolved
in aCSF for ex vivo experiments. Fast synaptic transmission blockers
were gabazine (5 μM) and DNQX (20 μM) from Tocris and D-AP5
(50 μM) from Abcam. Urethane was dissolved in MiliQ water.
2.5. Statistical analysis of data
Experimental data were analyzed using the computer program
GraphPad Prism (v. 5.01, GraphPad Software, Inc). The electrophysio-
logical data were analyzed by paired t test when two situations were
compared and one-way analysis of variance (ANOVA) followed by
post-hoc comparisons using the Newman Keuls to compare different
groups. The ﬁring pattern of STN neurons was analyzed using Fisher's
exact test. The level of statistical signiﬁcance was set at p b 0.05. Data
are presented as group means ± standard error of the mean (SEM).
3. Results
3.1. Characterization of 5-HT and buspirone-effects on STN neurons in
control brain slices
First of all, to validate our STN preparations we decided to study the
well known effect induced by 5-HT on STN neurons. For that purpose,Fig. 2. 5-HT ex vivo induces an excitatory effect on STN-neurons. (A) Example of a ﬁring-rate
majority of the cells studied) bydifferent concentrations of 5-HT (30 μM,1min; 3 μM,1.5min; 1
of the drug. (B) Pulled data from ﬁve paired normalized excitatory responses induced by 5
(C) Example of a biphasic effect induced by 5-HT (30 μM) on the basal ﬁring rate. (D) Pulled
100635 (1 μM) completely eliminated the inhibitory component (n = 5).41 neurons were studied before and after a bath application of 5-HT.
The majority of these cells (n = 39) spontaneously ﬁred regular action
potentials at a mean rate of 11 ± 1 Hz. Only two cells did not show
spontaneous ﬁring. As it has been previously described (Stanford
et al., 2005) not all of these 41 neurons responded in the same way to
the perfusion with 5-HT (30 μM). The main effect induced by 5-HT
was a reversible increase in STN-neuron ﬁring rate in 31 out of 41 neu-
rons, a percentage also observed by others (Stanford et al., 2005). On av-
erage, ﬁring rates increased moderately and in a concentration-
dependent manner in the presence of 5-HT (Fig. 2A). 5-HT (30 μM) in-
creased the ﬁring rate by 253 ± 30% (n = 29) in these cells. 5-HT in-
duced ﬁring activity on two silent cells but the magnitude of the effect
could not be quantiﬁed as the percentage change had to be calculated
according to the basal ﬁring value. The excitatory effectwas notmediat-
ed through 5-HT1A-receptor activation since perfusion with the 5-HT1A
antagonist, WAY-100635 (1 μM), for at least 10 min had no effect on
basal ﬁring rate or on the excitatory responses induced by 5-HT
(30 μM) (n = 5, paired t test p N 0.05) (Fig. 2B). Only in two cases, the
neuron recorded responded to 5-HT (30 μM)with a decrease in the ﬁr-
ing rate and in 3 out of 41 no effectwas observed. Interestingly, ﬁve cells
responded in a robust and repeatable biphasicmanner (Fig. 2C). In these
cells 5-HT induced ﬁrstly a signiﬁcant 64 ± 16% reduction of the ﬁring
rate (paired t test, p b 0.01) immediately followed by an increase of
the ﬁring rate above the basal frequency (54 ± 12%, p b 0.05, n = 5).
Subsequent WAY-100635 (1 μM) perfusion speciﬁcally and completely
abolished the inhibitory component of the biphasic response indicating
that it was mediated by the activation of the 5-HT1A receptor (Fig. 2D).
The excitatory component did not change after WAY-100635
application.
We have previously shown that a STN lesion decreases the anti-
dyskinetic effect of buspirone in vivo (Aristieta et al., 2012). Here, we
considered to investigate the possible direct effect of buspirone onrecording (spikes/10s) of a STN neuron showing the stimulatory effects induced (in the
μM,2min). The horizontal bar indicates demoment and the duration of the bath perfusion
-HT (30 μM) before and after the bath perfusion of WAY-100635 (WAY; 1 μM; n = 5).
data from ﬁve biphasic responses induced by 5-HT showing that bath perfusion of WAY-
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buspirone was tested in 51 STN neurons where it exerted a limited and
variable effect depending on the cell recorded. In fact, bath application
of buspirone (10–30 μM) failed to induce any effect in 31 of the studied
cells (61%). On the other hand, in 14 out of 51 studied cells, buspirone
induced a signiﬁcant 45 ± 7% inhibition of the ﬁring rate (n = 14).
Different concentrations of buspirone were used, 10 μM and 30 μM,
but since the magnitude of the inhibitory effect was similar in both
sets of experiments (t test, p N 0.05), all data were pooled together.
The inhibitory effect exerted by buspirone was slow to wash out but
easily reversed and prevented by a bath perfusion of the slice with
WAY-100635 (4± 15% change, paired t test; p b 0.05, n= 6). A second
application with buspirone failed to alter the basal ﬁring rate in the
presence of WAY-100635 (1 μM) (−6 ± 3% change, p N 0.05; n = 4)
(Fig. 3A and B). Buspirone rarely induced an excitatory effect (3 out of
51 cells), increasing the ﬁring rate by 54± 12% (Fig. 3C and E). Interest-
ingly, buspirone also exerted an unusual biphasic response in 3 STN-
neurons characterized by an excitatory response (78 ± 22%) immedi-
ately followed by a 56± 21% inhibitory one (Fig. 3D and E). Altogether,
whilst 5-HT main effect was excitation (31/41), buspirone's key effect
was inhibition only in 14 out of 51 studied neurons (Fig. 3F).Fig. 3. The inhibitory effect induced by buspirone ex vivo on STN-neurons is mediated by the 5-H
(30 μM) induces an inhibitory response reversed and prevented by a perfusion ofWAY-100635
and after the bath perfusion ofWAY-100635 1 μM (n=4, paired t test *p b 0.05). (C) Example o
(D) a biphasic effect. (E) Pooled data from three stimulatory and three biphasic responses induTo better characterize the buspirone effect, a series of supplementa-
ry experiments were performed in the presence of fast synaptic trans-
mission blockers consisting in the GABAA receptor antagonist gabazine
(5 μM), the selective NMDA receptor antagonist D-AP5 (50 μM) and
the AMPA and kainate receptor antagonist DNQX (20 μM). 23 STN neu-
rons were recorded in the presence of the fast synaptic transmission
blockers. These neurons showed a regular ﬁring frequency (11.4 ±
1.5 Hz) which slightly changed to 12.5 ± 1.7 Hz (paired t test, n = 19,
p b 0.05) after 5 min of bath perfusion with the blockers. As shown in
the Supplementary Fig. 1, all effects induced by buspirone (inhibition,
stimulation and biphasic response) were almost completely blocked
by the synaptic transmission blockers perfusion.
3.2. Characterization of buspirone-effect on STN neurons in control
anesthetized rats
We studied the effect of buspirone on subthalamic neuronal activity
in anesthetized rats. For that purpose, basal electrophysiological param-
eters of STN neurons (n = 23) were recorded over a period of 5 min
before and, at least, 20 min after the administration of buspirone (4
and8mg/kg i.p.) (Fig. 4). All cells recorded displayedmost characteristicT1A receptor. (A) Example of a ﬁring-rate recording (spikes/10s) showing how buspirone
(1 μM). (B) Pooled data from four paired inhibitory responses induced by buspirone before
f a ﬁring-rate recording showing how buspirone (10 μM) induces a stimulatory effect and
ced by buspirone. (F) Proportions of different effects induced by 5-HT and buspirone.
Fig. 4. The effects induced by buspirone in vivo on STN neurons are mediated by the 5-HT1A receptor. (A) Example of a ﬁring-rate recording (spikes/10s) showing the inhibitory effect of
intraperitoneal (i.p.) administration of buspirone (4 mg/kg). (B) Histograms illustrating the mean ﬁring rate of STN neurons before and after the administration of buspirone (4 mg/kg;
n = 12) and (8 mg/kg; n = 11) and with the pre (0.1 mg/kg; n = 5) and post administration (0.5 and 1.5 mg/kg; n = 4) of WAY-100635. Data are expressed as mean ± SEM. (paired
t test ***p b 0.001; **p b 0.01 vs. corresponding basal value) (C) Example of a ﬁring-rate recording showing the inhibitory effect of the administration of buspirone (8 mg/kg i.p.) plus the
reversion induced byWAY-100635 (0.5 and1.5mg/kg i.p.) on the STNneuronsﬁring rate. (D)Histograms illustrating themean coefﬁcient of variation (percent) of STNneuronsbefore and
after the administration of buspirone (4mg/kg; n= 12) and (8mg/kg; n= 11) andwith the pre (0.1mg/kg; n= 5) and post administration (0.5 and 1.5mg/kg; n= 4) ofWAY-100635.
Data are expressed as mean ± SEM. (paired t test ***p b 0.001; **p b 0.01; *p b 0.05 vs. corresponding basal value). (E) Example of a ﬁring-rate recording showing no effect exerted by
WAY-100635 (0.1 mg/kg i.p.) but the prevention of buspirone-inhibitory effect. (F) Distributions of ﬁring patterns of STN neurons before and after the administration of buspirone and
with the pre and post administration of the antagonist (Chi-squared (χ2) test ***p b 0.001; **p b 0.01 vs. corresponding basal value).
Table 1
Electrophysiological parameters of STN neurons.
Control
(n = 33)
Sham L-DOPA
(n = 6)
Lesion
(n = 5)
Dyskinetic
(n = 7)
Basal Firing Rate (Hz) 8.1 ± 0.3 7.4 ± 1.2 13.0 ± 1.1⁎ 14.7 ± 2.8⁎
Coefﬁcient of variation (%) 43 ± 2 52 ± 10 56 ± 15 124 ± 12⁎
Firing pattern (%)
Burst/Tonic/Random 70/30/− 67/33/− 50/50/−# 64/27/8#
Rats were treated daily with saline or L-DOPA 6 mg/kg in combination with benserazide
12 mg/kg, s.c. for at least 21 days. All neurons were recorded 24 h after the last injection
of saline or L-DOPA. Each value represents the mean ± SEM of (n = number of animals).
Each cell was recorded for 180 s.
⁎ p b 0.05; one-way ANOVA, Newman-Keuls post-hoc.
# p b 0.05; Fisher exact test.
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(Aristieta et al., 2012; Morera-Herreras et al., 2011) (Table 1). However,
the proportion of busty cells was high compared to our previous studies
what may be attributed to gender differences as shown in PD patients
(Mrakic-Sposta et al., 2008). In control rats, buspirone administration
decreased the ﬁring rate of every STN neuron tested in a dose related
manner. Thus, buspirone 4 mg/kg reduced the ﬁring rate by 35 ± 7%
(p b 0.01, paired t test; n = 12) (Fig. 4A and B) and 8 mg/kg produced
an inhibition of 76 ± 5% with respect to the basal values (p b 0.001,
paired t test; n = 11) (Fig. 4B and C). This inhibitory effect was slowly
reversed to basal levels after 60 min. Buspirone also modiﬁed the
coefﬁcient of variation of the cells, making them more irregular, (54%
for 4mg/kg and 63% for 8mg/kg; p b 0.01; paired t test) (Fig. 4D). Firing
pattern of STN neurons was also signiﬁcantly altered after buspirone
41A. Sagarduy et al. / Experimental Neurology 277 (2016) 35–45administration, decreasing the percentage of STN neurons discharging in
burst (p b 0.001; χ2 test= 13.33 and χ2 test= 51.11, for 4 and 8mg/kg,
respectively) (Fig. 4F). Also, buspirone8mg/kg, but not 4mg/kg, induced
a random pattern in a 30% of the studied population (Fig. 4F).
We next attempted to reverse the inhibitory effect induced by
buspirone with a 5-HT1A receptor antagonist. For this purpose, WAY-
100635 (0.5 and 1.5 mg/kg i.p.) was administered 10–15 min after the
administration of buspirone (8 mg/kg i.p.). After a dose of 8 mg/kg of
buspirone, 1.5 mg/kg but not 0.5 mg/kg of WAY-100635 (i.p.), fully
reversed the inhibitory effect induced by buspirone in the ﬁring fre-
quency (reversal effect 111 ± 5%; F(3,9) = 14.97, p b 0.0001, one-way
ANOVA; n = 4) (Fig. 4B and C). Furthermore, the highest dose of
WAY-100635 also reversed the effect exerted by buspirone on the
regularity of these neurons, bringing back the coefﬁcient of variation
to basal values (41 ± 5%; F(3,9) = 7.58, p b 0.01, one-way ANOVA)
(Fig. 4D). The ﬁring pattern of these neurons returned to basal condi-
tions after the administration of WAY-100635 (p b 0.001, Fisher
exact test) (Fig. 4F). Next, we applied lower doses of WAY-100635
(0.1 mg/kg, i.p.) prior to buspirone administration (15 min). In this
case,WAY-100635had no effect on STNﬁring frequency but completely
blocked the inhibitory effect of buspirone (F(2,14) = 1.22, n = 5;
p N 0.05, one-way ANOVA) (Fig. 4C and D). However, WAY-100635
did not block the effect of buspirone on the coefﬁcient of variation,
which became more irregular after buspirone administration (70 ±
9%) (F(2,8) = 3.47, p b 0.05, one-way ANOVA) (Fig. 4D). Interestingly,
the administration of WAY-100635 turned neurons more bursty (60%
before and 100% after the administration ofWAY-100635) as previously
shown (Aristieta et al., 2014). This modiﬁcation was reverted after
buspirone was applied (bursty cells: 40%) (p b 0.01, Fisher exact test)
(Fig. 4F).
To better characterize buspirone effect, buspirone was injected into
the STN near to the STN neuron that was being recorded. In this case
buspirone caused inhibition only in 2 out of 7 recorded neurons (Fig. 5).3.3. Characterization of buspirone-effect on STN neurons in 6-OHDA
lesioned and dyskinetic rats
Next we studied the effect of buspirone in three groups with differ-
ent conditions: sham L-DOPA (n = 6), 6-OHDA lesioned (n = 5) and
6-OHDA lesioned plus L-DOPA (n = 7) rats. Firstly, the spontaneous
electrical activity of STN neurons from these rats was recorded and, as
we and others have previously described, we found that the STN
becomes hyperactive after dopamine depletion (Aristieta et al., 2012;
Bergman et al., 1994; Hassani et al., 1996; Morera-Herreras et al.,
2011). As described in Table 1, ﬁring rate in STN neurons from both
6-OHDA lesioned and dyskinetic rat groups as well as the coefﬁcient
of variation of dyskinetic rats were signiﬁcantly higher than in the con-
trol rat group (F(3,47) = 10.86 and F(3,47) = 45 respectively; p b 0.001,
one-way ANOVA). Firing pattern in 6-OHDA lesioned and dyskineticFig. 5. (A) Example of a ﬁring-rate recording (spikes/10s) showing the inhibitory effect of local
10s) showing the lack of effect after local administration of buspirone (0.25–2 nmol).rats was also different than that found in the control group (p b 0.01,
χ2 test = 8.33; p b 0.05, χ2 test = 8.42 respectively).
In sham L-DOPA rats, in the sameway as in control rats, we observed
that buspirone administration (8 mg/kg i.p.) induced a 58 ± 12%
decrease on the ﬁring rate (paired t test, p b 0.01; n = 6) (Fig. 6).
There was also a decrease in the regularity of these neurons, shown by
an increase in the coefﬁcient of variation from 52± 10% in basal condi-
tions to 98± 12% after buspirone administration (paired t test, p b 0.05;
n=6) (Fig. 6D). In this group of rats the amount of neurons discharging
in burst did not change after buspirone administration, however, a 16%
of neurons turned to show a random pattern (p b 0.001, χ2 test =
21.89) (Fig. 6F).
Interestingly, buspirone (8 mg/kg i.p.) did not modify the ﬁring rate
of STNneurons neither in 6-OHDA lesioned rats (before 13.0±1.1Hz vs
after buspirone 12.5 ± 1.3 Hz; n = 5) (Fig. 5B and C) nor in dyskinetic
rats (before 14.7 ± 2.8 Hz vs after buspirone 19.4 ± 4.6 Hz; n = 7)
(Fig. 5B and E). Also, the neuron regularity from both groups remained
unchanged, as it is shown by the absence of change in the coefﬁcient of
variation (lesioned, 42 ± 7% vs 53 ± 12% and dyskinetic 130 ± 12% vs
139 ± 10%, before vs after buspirone) (Fig. 5D). On the contrary, burst-
ing pattern of STN neurons decreased after buspirone administration in
6-OHDA lesioned (before 40% vs after buspirone 20%, p b 0.01, χ2 test=
9.52) and dyskinetic rats (before 57% vs after buspirone 29%; p b 0.001,
χ2 test = 19.79) (Fig. 5F).
4. Discussion
We have previously shown that the 5-HT1A receptor agonist
buspirone not only improves dyskinesias in a rat model of LID but also
reverses some key molecular changes related to these motor complica-
tions (Azkona et al., 2014). Interestingly, these important effects were
attenuated when the STN was lesioned (Aristieta et al., 2012). Here,
we show that buspirone reduces the ﬁring rate of STN neurons through
the activation of 5-HT1A receptors by a complex mechanism. Buspirone
ex vivo only caused inhibition in a small population of neurons while
in vivo, when systemically applied, all recorded neurons from control
rats were clearly inhibited. Furthermore, in 6-OHDA-lesioned rats
chronically treated or not with L-DOPA, buspirone completely failed to
induce any effect on STN activity suggesting that the dopaminergic
system is also implicated.
The STN, and in general the basal ganglia, is innervated by 5-HT-rich
ﬁbers coming primarily from neurons in the DRN (Di Matteo et al.,
2008; Liu et al., 2007; Mori et al., 1985). It has been shown that not
only 5-HT1A, 5-HT2C and 5-HT4 receptor-mRNAs but also the correspon-
dent receptors are expressed in STN cells (Eberle-Wang et al., 1997;
Grossman et al., 1993; Maroteaux et al., 1992; Pazos et al., 1985; Pazos
and Palacios, 1985; Pompeiano et al., 1992; Waeber et al., 1996). Also,
5-HT1B/D-receptors are located in terminals of the motor cortex and
the external segment of the globus pallidus neurons that project to
the STN (Hannon and Hoyer, 2008; Hoyer et al., 2002; Sari et al.,administration of buspirone (0.25–1 nmol). (B) Example of a ﬁring-rate recording (spikes/
Fig. 6. Effect of the administration of buspirone (8 mg/kg i.p.) on the electrical activity of STN neurons of control, sham L-DOPA, 6-OHDA lesioned and dyskinetic rats. (A) Example of a
ﬁring-rate recording (spikes/10s) showing the inhibitory effect of buspirone administration (8 mg/kg i.p.) in sham L-DOPA rats. (B) Histograms illustrating the mean ﬁring rate of STN
neurons before and after the administration of buspirone (control (n = 11); sham L-DOPA (n = 6); 6-OHDA lesioned (n = 5) and dyskinetic (n = 7)); **p b 0.01 vs. corresponding
basal value (Student's t test). Data are expressed as mean ± SEM. (C) Example of a ﬁring-rate recording showing the absence of effect of buspirone administration (8 mg/kg i.p.) in
6-OHDA lesioned rats. (D) Mean coefﬁcient of variation (percent) of STN neurons before and after the administration of buspirone (control (n = 11); sham L-DOPA (n = 6); 6-OHDA
lesioned (n = 5) and dyskinetic (n = 7)); *p b 0.05 vs. corresponding basal value (Student's t test). Data are expressed as mean ± SEM. (E) Example of a ﬁring-rate recording showing
the absence of effect of buspirone administration (8mg/kg i.p.) in dyskinetic rats. (F) Distributions of ﬁring patterns of STN neurons before and after the administration of buspirone in the
different groups; ***p b 0.001; **p b 0.01 vs. corresponding basal value (Chi-squared (χ2) test).
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selective 5-HT receptor antagonist aswell as lesioning the DRN increase
the ﬁring rate of STN neurons (Aristieta et al., 2014; Liu et al., 2007).
However, according to the literature, the effects of 5-HT on STN neurons
ex vivo are an increase in the ﬁring rate, without changing the ﬁring
pattern, through 5-HT2C and 5-HT4 receptors activation and also a less
frequent inhibition through 5-HT1A/B receptor activation (Flores et al.,
1995; Stanford et al., 2005; Xiang et al., 2005; Shen et al., 2007). In our
hands, 5-HT ex vivo induces a reversible increase in STN-neuron ﬁring
rate in a 76% of the studied neurons, in a comparable proportion to
the 82% described by Stanford et al. (2005) and in agreement with the
inward current described for the 64% of the patch-clamped STNneurons
(Shen et al., 2007). 5-HT induced rarely an inhibitory effect in a 5% of the
recorded cells, in a similar way it has been described before. Finally, a12% of the recorded neurons responded to 5-HT with a biphasic
response as the 8% shown previously by Stanford et al. (2005) and in
agreement with the biphasic current found in a 19% of STN neurons by
Shen et al. (2007). Furthermore,we have shownhere that the inhibitory
phase induced by 5-HT ismediated through the activation of the 5-HT1A
receptor as it was prevented by the selective antagonist WAY-100635,
compared to what has been shown in those previously cited works
where it was blocked using the less selective 5-HT1A/B receptors antag-
onist WAY-100135. When we applied buspirone ex vivo it failed to
induce any effect in the 61% of the studied neurons and primarily
inhibited the ﬁring rate only in a 27% of the studied cells through the
activation of the 5-HT1A receptor. Buspirone also induced an excitatory
effect in a 6% and a biphasic effect in another 6% of the recorded cells.
These results agree with the fact that 5-HT also induces inhibition in a
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expressed in a selected and scarce group of STN neurons (Stanford
et al., 2005). However, 5-HT, a full agonist, inhibits the STN in only
the 5% of the recorded cells, less than the 27% induced by buspirone.
This discrepancy could be explained by the probable 5-HT interference
co-activating other excitatory receptors (5-HT2C-4) as well, which
would eclipse the 5-HT1A receptor effect, especially when these
inhibitory receptors were expressed in lower proportion. Altogether,
the STN appears to be a very heterogeneous nucleus composed by a
population of neurons which show different responses depending on
the array of serotonergic receptors expressed, being the inhibitory
response mediated by 5-HT1A receptors present in a small proportion
of neurons.
It has been previously shown that the 5-HT1A full agonist 8-OH-
DPAT administered systemically after 5-HT depletion, or locally admin-
istered in the STN in vivo, inhibits STN neuron activity (Aristieta et al.,
2014). Here, we show that also buspirone dose-dependently inhibits
the ﬁring rate on every STN neuron recorded in control rats through
the activation of the 5-HT1A receptors. As buspirone has been described
as a partial agonist at post-synaptic receptors but as a full agonist at DRN
5-HT1A somatodendritic autoreceptors (Sprouse and Aghajanian, 1988;
Valdizan et al., 2010), collectively this STN inhibition could be attributed
to a direct effect mediated by the activation of the postsynaptic 5-HT1A
receptors located in the STN itself or via an indirect effect perhaps via
DRN autoreceptors. In this sense, it has been recently shown that either
5-HT1A-receptor agonists that preferentially activate post-synaptic
5-HT1A-receptor, such as F15599, or 5-HT1A-receptor agonist that pref-
erentially activate pre-synaptic 5-HT1A-receptor like F13714, all reduce
LID in animal models of PD (Huot et al., 2015; Iderberg et al., 2015a).
Also, a potent and efﬁcacious pre- and post-synaptic 5-HT1A receptor
agonist, F13640, has been recently demonstrated to be a promising
antidyskinetic drug (Iderberg et al., 2015b). Nevertheless, present
ﬁndings indicate that buspirone effect on STN neurons involve indirect
mechanisms: (1) the application of a supramaximal concentration of
buspirone ex vivo, in a preparation that preserves only afferent termi-
nals to the STN, failed to reduce the ﬁring rate in the majority of the
recorded cells, (2) ex vivo buspirone effects were almost completely
prevented by the presence of fast synaptic transmission blockers and
(3) in vivo local injection of buspirone into the STN affects to a small
number of recorded STN neurons.
Indeed, an indirect effect mediated by 5-HT1A receptors in the
cortex, globus pallidus, substantia nigra pars compacta, thalamus or
DRN cannot be excluded, since the STN receives input from all of these
structures that are affected by buspirone (Canteras et al., 1990;
DeLong and Wichmann, 2007; Lanciego et al., 2004; Nambu et al.,
2002; Parent et al., 2011). Interestingly, it was already described in
1995 that buspirone at 4 mg/kg i.p. not only reduced glucose metabo-
lism in the cortex, thalamus, globus pallidus and DRN but also in the
STN of the rat (Freo et al., 1995).
Buspirone also reduces 5-HT synthesis rate in various rat brain struc-
tures including basal ganglia and the DRN (Okazawa et al., 1999) and
totally inhibits DRNneurons (VanderMaelen et al., 1986). It is important
to point out that in anesthetized rats buspirone signiﬁcantly increases
the levels of dopamine in cortex and striatum (Silverstone et al., 2012)
whereas, activation of 5-HT1A-receptors attenuates the increase in
extracellular dopamine derived from exogenously administrated L-
DOPA in the striatum of 6-OHDA lesioned rats (Kannari et al., 2001).
Moreover, when administered to dyskinetic PD patients, buspirone
not only reduces L-DOPA-evoked striatal synaptic dopamine increases
but also attenuates LIDs (Politis et al., 2014). Interestingly, we observed
that in 6-OHDA lesioned rats either treated with saline or with L-DOPA
(dyskinetic rats) buspirone had no effect on the neuronal activity of
the STN. The fact that nigrostriatal pathwaymust be intact for buspirone
to exert its inhibitory effect in the STN suggests that the effect may be
mediated by dopamine. In this sense, immunohistochemical studies
have demonstrated the presence of both D1 and D2 dopamine receptorson STN cells (Bouthenet et al., 1987; Boyson et al., 1986; Flores et al.,
1999; Johnson et al., 1994). Several ﬁndings indicate that the response
of STN neurons to dopaminergic drugs is altered after dopaminergic
denervation of the basal ganglia. Thus, apomorphine, a non selective
dopamine receptor agonist, and D2 dopamine receptor agonists admin-
istration induces a decrease in the ﬁring rate of STN neurons in intact
rats and do not have effect on 6-OHDA lesioned rats (Hassani and
Feger, 1999). On the other hand, as it has been consistently shown
that the 5-HT system is severely affected after degeneration of
nigrostriatal dopaminergic neurons, a modulation of this system may
be also considered. However, although several studies have observed a re-
duction of 5-HT1A receptor binding sites in the DRN of patients with PD
(Doder et al., 2003) and in MPTP-treated monkeys (Frechilla et al.,
2001) no changes have been reported concerning the density of 5-HT1A
receptors in the striatum (Azkona et al., 2014). According to that, al-
thoughWang et al. (2009) reported a severe reduction in 8-OH-DPAT po-
tency in the DRN after a unilateral lesion of the nigrostriatal pathway, we
did not observe it in our model (Miguelez et al., 2014).
5. Conclusions
In conclusion, our results show that buspirone exerts its inhibitory
effect through 5-HT1A receptors by a complex mechanism that may
involve the dopaminergic system.We also found that the antidyskinetic
effect of buspirone does not imply a direct modulation of the electrical
activity of the STN. Dyskinesia is a debilitating motor complication
that appears in the majority of the patients that receive chronic treat-
mentwith L-DOPA. In spite of numerous efforts to develop a pharmaco-
logical treatment, there is not yet any new licensed drug to treat or
prevent LIDs better than amantadine which clinical use is limited
because of its partial efﬁcacy and some important tolerability issues
such as constipation, dizziness and hallucinations (Pahwa et al., 2015).
It is essential to characterize drug targets to develop new treatments.
In this sense the 6-OHDA lesioned rat model has proved to be a useful
tool for studying both PD and the side effects resulting from treatment
with L-DOPA (Bezard and Carta, 2015; Miller and Beninger, 1991;
Schallert et al., 2000; Ungerstedt, 1971). Our present results show that
response to buspirone depends on dopaminergic innervation stressing
the importance of animalmodel to identify new antidyskinetic pharma-
cological tools.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.expneurol.2015.12.005.
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